ABUS vs PATH
Arbutus Biopharma Corp (ABUS) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ABUS and PATH stock pages for the full models.
Not investment advice.